Fresh analysis reveals that individuals who stop using new GLP-1 drugs like Mounjaro or Wegovy may regain reduced body mass at a significantly accelerated pace than those who halt traditional diet and exercise programs.
Findings released in a prominent medical journal demonstrates that while obese people can lose substantial amounts of their body weight while using the jabs, the mass is regained at an estimated rate of 0.8 kg per month after stopping.
"Users purchasing such treatments must be cognizant of the risk of fast weight regain when the therapy is stopped," warns expert Dr. Susan Jebb.
Such speed of recovery implies a return to original weight in about 18 months.
Analyzing Approaches
The study, which looked at 37 of studies involving over 9,000 of patients, compared the effects of the injectable medications with other pills.
The team emphasize that people who lose weight through dieting generally experience a more gradual creep back—around 100 grams monthly—once they finish.
Explaining the Quick Regain
Nutrition scientists believe the way of the drugs accounts for the heightened regain.
GLP-1 drugs mimic a body's own chemical called glucagon-like peptide-1, which moderates appetite.
"Long-term administration of GLP-1 levels several times higher than normal may cause the body to generate a reduced amount of its endogenous hormone, and may also diminish sensitivity to its effects," noted Dr. Adam Collins, a nutrition expert.
"Discontinuation of this GLP-1 'fix' leads to appetite is no longer kept in check, making excessive eating much more probable."
An Ongoing Issue?
Health authorities suggest the injections for people with obesity-related medical conditions, alongside recommended diet and exercise modifications.
Many experts argue that, due to the likelihood of relapse, the treatment is often life-long.
This perspective is supported by pharmaceutical companies, who say that the results "underscore the long-term nature of obesity," comparing it to managing diseases like high blood pressure.
Patient Experiences
People who have stopped the jabs report a sudden resurgence of appetite.
"It was like something activating and you're instantly extremely hungry," said a patient.
This challenge is exacerbated if patients have not adopted permanent dietary or behavioural changes during therapy.
Significant Interest
Figures suggest that a significant number of people in the UK have tried weight-loss jabs in the past year, with demand remaining high.
- Adoption is greater among females than males.
- The middle-aged demographic shows the highest usage rates.
- Many access the drugs through private prescriptions rather than public health services.
Finally, experts stress that while the jabs are powerful tools for shedding pounds, they are not a permanent cure and long-term success hinges on ongoing lifestyle support.